The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.
about
Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infectionActive and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasisFungicidal monoclonal antibody C7 binds to Candida albicans Als3.Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.Candida infections of the genitourinary tract.FungalRV: adhesin prediction and immunoinformatics portal for human fungal pathogens.The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.Vaccines for invasive fungal infectionsNovel strategies to fight Candida species infection.Luminescent-activated transfected killer cells to monitor leukocyte trafficking during systemic bacterial and fungal infection.Vaccines in the treatment of invasive candidiasis.Adaptive immune responses to Candida albicans infection.Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasisConsiderable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.Invasive fungal infections in acute leukemia.Developments in the treatment of candidiasis: more choices and new challenges.Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans.Interactions of the fungal pathogen Candida albicans with the host.The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family--a sticky pursuitSaccharomyces cerevisiae: a versatile eukaryotic system in virology.Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.Innate immune cell response upon Candida albicans infectionImmune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis.Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunityThe inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis.Functional control of the Candida albicans cell wall by catalytic protein kinase A subunit Tpk1.Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy.A mass spectrometric view of the fungal wall proteome.Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections.Candida antigens and immune responses: implications for a vaccine.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.Threonine-rich repeats increase fibronectin binding in the Candida albicans adhesin Als5p.Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.A Candida albicans regulator of disseminated infection operates primarily as a repressor and governs cell surface remodeling.Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus.A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future.
P2860
Q28478751-5256DF59-DCEC-4526-98AC-5642AB58D872Q28744094-3AFD055C-0D76-442E-AC72-C13D4326793BQ33282525-88AD7176-6E87-4011-8946-04076F604456Q33521257-6BD2FBCB-985C-4C3C-B7C1-917E472900EEQ33825621-F5CF0F0C-4A96-4279-99F5-24EED6ACD5AAQ33874270-EBD7F01D-7712-42A7-8643-C5D03F65375DQ34601755-48971634-112B-41D0-8619-2B4DA369AF82Q35161720-B97A5B83-2413-44F3-8885-A6A02A068511Q35406737-8419B63D-C93E-42E2-84D2-57F186BFE47FQ35628658-28F270B6-8B40-4789-B82F-3F9181C53FCEQ36147010-4A753732-DA8D-4CD6-A3AD-A3909F96707EQ36147114-058F4A9C-AF72-47BF-875D-13D2A0484697Q36421907-E7398D55-BAF7-42EA-A369-C3B70C675DB2Q36497665-08720A0F-EE8F-44CF-8EF2-409C97BF5FB4Q36569183-CDDA5743-7E9F-4D22-AE0F-192EAED9A05FQ36612597-134A9EE4-A4C5-44E9-B396-89ABCBAABE18Q36623050-2E4D0F9A-AC1D-4CB4-BCAA-9105B4DAFAFAQ36692630-DC27D6E6-EE03-4066-BA46-31C6B913F8A2Q36895656-F1E38EFE-7C90-4B20-AF86-3325D77FDDA1Q36898452-CA860786-4B80-48CB-A181-D73AA86B3266Q36939626-7BDB2ED0-3495-4C24-8A53-12842FE29EA6Q36967384-D83126C9-A8A9-4B5D-967D-41ED57222D6EQ37116545-1424C9BA-E66B-4656-B5FD-F6466E5F2887Q37262877-8A1EE021-8DFD-4A87-8AC6-8949A5720EACQ37267375-F65F353D-FED3-4BAA-B7B7-C82DAD261432Q37280340-6F23EF0C-2401-4315-9B3A-9295B7756036Q37612479-FE5208C6-D90B-4DF0-88BC-0DC8B65D7DEEQ37627358-4BFE7A02-22F3-4DF0-8F8D-E2727B56F381Q37763270-EF724D55-DC48-4B45-B4CB-777214837730Q37921299-6D89FE4B-3AF5-4A62-93C6-9955347AE8FBQ38067451-A1FD7F95-E759-49DA-B2C9-515872E640F9Q38222636-B7874A89-5831-409F-8FF3-A2815A43969DQ38264288-249CBB01-F447-46BE-916C-65EC742F36C0Q38499396-6C1FA9B3-DD00-4E2F-BD74-8A8F9D0EAB91Q40183727-1A1B674C-0E2A-49FA-860F-C7D701253368Q40858980-34D56EEA-9179-4B01-84A0-ACBB43B8B21DQ41772064-5D3EB539-F98D-4DA2-BFD9-A67622C2F0F6Q52561594-42BBE26E-5683-4CD0-BB73-2C57C4C5AAAFQ53683158-6F7D492F-6D13-4BCD-8299-559EA5D8A676
P2860
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@en
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@nl
type
label
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@en
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@nl
prefLabel
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@en
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@nl
P2093
P2860
P1476
The anti-Candida albicans vacc ...... nt and immunocompromised mice.
@en
P2093
Ashraf S Ibrahim
Brad J Spellberg
Carter L Myers
John E Edwards
Scott G Filler
Valentina Avenissian
P2860
P304
P356
10.1128/IAI.73.9.6191-6193.2005
P407
P577
2005-09-01T00:00:00Z